AZD9977 is the first mineralocorticoid receptor modulator in clinical development exerting similar organ protection as eplerenone with minimal urinary electrolyte effects in preclinical studies. The aim was to perform the initial clinical assessment of AZD9977.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Mineralocorticoid receptor (MR) antagonists improve outcomes in heart failure and chronic kidney disease, but cause hyperkalaemia.
• MR modulators may provide the benefits of MR antagonists, but without the risk for hyperkalaemia.
• AZD9977 behaves as an MR modulator in preclinical experiments, retaining the organ-protective effects without affecting electrolytes.
• Recent preclinical data indicate that AZD9977 can affect urinary electrolyte excretion in the presence of fludrocortisone, but not in the presence of aldosterone.
Introduction
Chronic kidney disease (CKD) is a global health burden with increasing prevalence affecting approximately~11% of the population [1] . Current CKD therapy is primarily based on using angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) [2, 3] . Despite optimal therapy many patients progress to end-stage renal disease, which requires dialysis and/or transplantation. CKD patients also have a disproportionate increase in the risk of cardiovascular (CV) disease, which remains the leading cause of mortality in CKD patients and contributes to the high economic burden of the disease [4, 5] . There is thus an urgent need to develop novel therapies to halt or reverse CKD progression and reduce CV events. Preclinical and preliminary clinical evidence suggests that blockade of mineralocorticoid receptor (MR) may offer a novel, efficacious treatment for CKD. Addition of MR antagonists (MRAs) spironolactone, eplerenone or finerenone on top of ACEi/ARB therapy reduces proteinuria [6, 7] , and small intermediate-term studies with MRAs on top of ACEi/ARB suggest that MRA treatment may lead to glomerular filtration rate stabilization [8, 9] . The benefits of MRAs may be independent of blood pressure effects [10, 11] . MRAs reduce mortality and hospitalizations in congestive heart failure (CHF) [12] [13] [14] , including in CHF with mild to moderate CKD. A single small trial has suggested that spironolactone may provide a significant reduction in CV events in haemodialysis patients, and larger outcome studies in dialysis patients are ongoing [15] .
Efficacy data thus support the development of MRAs for treatment of CKD, but the increased risk for hyperkalaemia limits their use, particularly in high risk patients with diabetes and advanced CKD. The increased hyperkalaemia risk is a consequence of the effects of MRAs on urinary electrolyte excretion. The endogenous MR agonist aldosterone regulates sodium and potassium balance, predominantly by promoting sodium resorption and thereby sodium-dependent potassium excretion through activation of ENaC in the collecting duct [16, 17] . Blockade of aldosterone action thus causes potassium retention and increases the risk of developing hyperkalaemia.
Urinary Na + /K + ratio has been proposed as a quantitative and translational mechanism biomarker for MR blockade following administration of single doses of MRAs and has been used in the preclinical and clinical development of novel MRAs [18, 19] . Whilst preclinical studies typically assess acute effects on urinary sodium and potassium in presence of high concentrations of the endogenous mineralocorticoid aldosterone, the orally available mineralocorticoid fludrocortisone is used in clinical studies. Fludrocortisone has previously been shown to have similar properties as aldosterone apart from its oral bioavailability and prolonged half-life [20] . AZD9977 is the first MR modulator evaluated in man. In preclinical studies AZD9977 exerts similar organ protective effects as eplerenone but is associated with minimal effects on urinary electrolytes up to the maximum exposure levels studied (>60 fold anticipated therapeutic exposure) [21] .
The purpose of the present studies was to determine the safety, tolerability and human pharmacokinetics of AZD9977 and to evaluate the effects of AZD9977 on urinary electrolyte excretion in presence of fludrocortisone.
Methods

Clinical studies
Two clinical studies were performed to evaluate AZD9977. Both studies were sponsored by AstraZeneca and performed at PAREXEL Early Phase Clinical Unit at Northwick Park Hospital, London, UK. The studies were approved by the Medicines & Healthcare products Regulatory Agency and the London -Brent Research Ethics Committee (REC reference: 15/LO/1030). All study subjects provided written informed consent.
Study 1 (D6400C00001, NCT02484729, EudraCT 2015-000877-11) was a Phase I, first-in-human study in healthy male subjects. The study was conducted in two parts (A and B). Part A employed a randomized, single-blind, placebo-controlled, sequential group design randomizing eight subjects 6:2 to AZD9977 or placebo in each group. The objectives were to assess safety/tolerability and pharmacokinetic parameters at each dose level. Sentinel dosing was employed. Part B employed a nonrandomized, open-label, single-dose, fixed-sequence cross-over design. The objective was to assess regional absorption of AZD9977 by administering AZD9977 oral suspension in an IntelliCap device programmed to release 40 mg at a constant rate over 12 h and compare the resulting pharmacokinetic profile with the profile of a 40 mg oral solution administered to the same subjects 1 week later [22] .
Study 2 (D6400C0004, NCT02532998, EudraCT 2015-002224-11) was a single-blind (with regards to AZD9977 and AZD9977 placebo), randomized, four-treatment, four-period crossover Williams design. The treatments administered were fludrocortisone (F), 200 mg AZD9977 + fludrocortisone (A + F), 100 mg eplerenone + fludrocortisone (E + F), and 200 mg AZD9977 + 100 mg eplerenone + fludrocortisone (A + E + F). In addition, a session was run before randomization where no treatment was administered. The intention of the treatment A + E + F was to assess if AZD9977 could attenuate the sodium excretion induced by eplerenone as observed in rodent studies [21] . Fludrocortisone was administered starting with 0.5 mg 2 h before the administration of eplerenone and AZD9977 or matching placebo, followed by 0.1 mg fludrocortisone administered every 2 h for 10 h. Food and fluid intake was controlled. Total sodium intake was 100 mmol day -1 and potassium intake was 80 mmol day
from the evening before dosing until 24 h post dose. To ensure adequate diuresis, subjects were instructed to drink 800 ml water over 4 h 12 h before dosing, 400 ml 2 h before dosing, followed by 200 ml every 2 h until 8 h post dose. Urine was collected during defined intervals, and subjects were instructed to empty their bladders completely at the end of each interval. Ln
is a sensitive marker of ENaC activity in distal tubule. Based on pharmacokinetic/pharmacodynamic modelling and Study 1 pharmacokinetic data from 2 to 8 h post administration of AZD9977 / eplerenone was selected as the primary time window to be studied. Primary endpoint was the sum of the natural logarithm of Na + /K + -ratio for three time intervals (2-4, 4-6 and 6-8 h) and was calculated for all treatment periods, including the no treatment session. It was analysed using a mixed linear model with treatment, period and sequence as fixed effects, subject within sequence as a random effect, and the no-treatment session as baseline covariate. Pharmacokinetic plasma and urinary samples for AZD9977 were collected in study 1 and plasma samples for AZD9977, eplerenone and fludrocortisone were collected in Study 2. AZD9977 and eplerenone levels were analysed in all subjects for all treatment periods using validated assays at Covance, but for fludrocortisone levels was estimated based on samples from five individuals. Fludrocortisone plasma samples were quantified using a method adapted from Ribot et al. [23] The safety parameters collected in both studies included adverse events, blood pressure, pulse, 12-lead digital electrocardiograms and laboratory assessments (including haematology, clinical chemistry and urinalysis panels).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [24] , and are permanently archived in the Concise Guide to PHARMA-COLOGY 2017/18 [25] .
Results
Study 1 recruited 62 subjects in part A and eight subjects in part B. In part A, doses from 5 mg to 1200 mg were explored. Subjects randomized to receive placebo in part A (n = 16) were not significantly different from subjects receiving AZD9977 (n = 46), as they were of similar age (30 vs. 33 years), weight (75.3 vs. 77.6 kg) and height (176 vs. 177 cm). Study 2 recruited 23 healthy volunteer subjects of similar characteristics.
Safety and tolerability
AZD9977 was safe and well tolerated by the healthy male subjects exposed in both studies. There were no serious adverse events (AEs), severe AEs or AEs leading to discontinuation reported. No adverse trends were observed in clinical laboratory results, 12-lead electrocardiograms, telemetry results or physical examination results in either study.
In Study 1 the predefined safety stopping criteria were not met at any evaluated dose, including 1200 mg. The incidence of AEs was 43.8% in subjects receiving placebo and 23.9% among subjects receiving AZD9977 at any dose. The adverse events reported by more than one subject in Study 1 were dizziness (one subject each on placebo, 5 mg, 25 mg and 200 mg), back pain (one subject each on 100 mg and 200 mg), contusion (two subjects on placebo) and skin irritation (two subjects on placebo).
Ten (43.5%) subjects experienced at least one AE in Study 2, and the frequency of AEs reported across treatment periods was similar. The most frequently reported AEs in Study 2 were headache and nasopharyngitis occurring in three (13.0%) subjects.
Pharmacokinetics
Following single oral suspension administration of AZD9977 in Study 1 dose-proportional pharmacokinetics were observed over the 5 mg to 200 mg dose range (Figure 1 ). At doses >200 mg saturable nonlinear kinetics were evident and the exposure achieved with 400 mg and 800 mg administered as single doses were similar. As solubility limited absorption was suspected, administration of AZD9977 was fractioned at subsequent administrations in Study 1. When 800 mg AZD9977 was administered as 200 mg h -1 the exposure more than doubled compared with 800 mg administered as a single dose. Absorption of AZD9977 was fast and following attainment of C max , the plasma concentration declined rapidly and virtually mono-exponentially with an elimination halflife of 2 to 3 h (Figure 1 ). Approximately 20% of the AZD9977 dose was excreted unchanged in urine. In Study 2. the pharmacokinetic parameters of AZD9977 was similar as in Study 1, also when coadministered with eplerenone ( Figure 2a ). Based on a subset of the subjects, the selected dosing regimen (0.5 mg followed by 0.1 mg every 2 h) for fludrocortisone resulted in stable concentration during the first 10 h post dosing (Figure 2b) , and exposure was in line with reported data [23, 26] .
The regional absorption of AZD9977 in humans was investigated using an Intellicap device in part B of Study 1 [22] . Based on the results, the extent of colonic absorption was deemed sufficient for controlled release formulation development (data not shown).
Effects on urine production and electrolyte excretion
AZD9977 did not appear to affect the volume of urine produced in healthy volunteers, whether administered as monotherapy or on top of fludrocortisone (data not shown).
In rodent studies, in presence of high plasma aldosterone levels, eplerenone, but not AZD9977, leads to increased sodium excretion. Coadministration of AZD9977 attenuates the effects on urinary electrolytes induced by eplerenone [21] . In contrast the outcome of the primary endpoint in Study 2 indicated that in the presence of fludrocortisone, AZD9977 at 200 mg exhibited a similar effect on urinary electrolytes as eplerenone in man, and the effects of AZD9977 and eplerenone were additive (Figure 3) . The additive effect of 200 mg AZD9977 to 100 mg eplerenone is consistent with a receptor pharmacology where only a fraction of MR is occupied by either compound, which is in line with the previously described dose dependent increased effect of eplerenone up to 1000 mg [18] . Treatment with fludrocortisone alone was significantly different from all other treatment periods with regards to the primary endpoint (P < 0.0001). Treatment with both eplerenone and AZD9977 on top of fludrocortisone resulted in an additive effect significantly different vs. all other treatment periods (P < 0.0001).
When the time-courses of the excretion of sodium and potassium were plotted ( Figure 4 ) the peak effect of eplerenone occurred later than for AZD9977, as expected considering the later C max of eplerenone ( Figure 2 ). The Na + /K + ratio shift induced by AZD9977 and eplerenone was mainly driven by increased sodium excretion (Figure 4) . Administration of AZD9977 and/or eplerenone at the selected doses did not fully reverse the effect of fludrocortisone, as the urinary Na + /K + ratio during the no treatment period was higher than during all four treatment periods. In conclusion AZD9977 exhibited similar pharmacodynamic effects as eplerenone in Study 2 under the experimental conditions used. The effects of AZD9977 on urinary sodium and potassium excretion were analysed retrospectively also in Study 1
Figure 1
Pharmacokinetics of AZD9977 in Study 1. Dose proportional kinetics were observed up to 200 mg. Fractioning of the dose into four doses over 3 h resulted in higher Cmax and exposure than could be achieved with single doses Figure 2 Pharmacokinetics of 200 mg AZD9977, 100 mg eplerenone and fludrocortisone in Study 2. Exposure of AZD9977 and eplerenone were similar when coadministered and when administered alone, indicating that the results were not influenced by any pharmacokinetic drug-drug interaction. The fludrocortisone dosing schedule resulted in a stable plasma concentration over the first 10 h following the administration of AZD9977 and/or eplerenone Initial development of MR modulator AZD9977 ( Figure 5 ), due to the unexpected effect of AZD9977 on urinary electrolyte excretion in Study 2. Study 1 was not prospectively designed or powered to assess urinary electrolyte effects, hence no formal statistical testing was performed on the data.
Discussion
Mineralocorticoid receptor antagonism benefits patients with congestive heart failure [12] [13] [14] , and potentially also patients suffering from CKD [8, 9] . Unfortunately, the use of MRAs may be hampered by hyperkalaemia, although the medical implications of MRA induced hyperkalaemia is subject of debate [27] . The organ protective effects of MRAs may not be dependent on the effects on urinary electrolyte excretion, as cardiac benefits have been noted in one trial with patients on dialysis [15] . MR modulators could be developed to separate the organ protective effects from the potassium retention, similar to how modulators of other nuclear receptors retain treatment benefits with fewer side effects [28, 29] . Furthermore, as hyperkalaemia is the dose limiting toxicity of selective MRAs, an MR modulator could in theory be administered at higher doses than MRAs, potentially achieving higher organ protective effects than MRAs.
AZD9977 is a novel MR modulator, which in preclinical studies exerts similar organ protective effects as eplerenone, with minimal urinary electrolyte effects. We report the first ever studies in man with a modulator of MR, providing a unique opportunity to explore novel aspects of MR pharmacology.
In Study 1, the first in man study, AZD9977 up to 1200 mg exhibited a safety profile in healthy volunteers consistent with the benign safety profile of traditional MR antagonists [18, 30, 31] . Pharmacokinetic parameters were in an acceptable range, despite a short t 1/2 . The need for a long plasma half-life and 24 h coverage has been questioned recently as finerenone (t 1/2 ≈ 2 h) exhibited similar or better antialbuminuric efficacy when 10 mg was given once daily compared to 5 mg twice daily [31, 32] . If once daily administration and 24 h coverage would be needed AZD9977 could be formulated in a controlled release formulation, as Figure 3 Urinary electrolyte excretion in Study 2. AZD9977 and eplerenone reversed the effects on urinary potassium and sodium excretion induced by fludrocortisone to a similar extent, and the effect appeared additive. This contrasted with experiments performed in rodents and using aldosterone. Fludrocortisone was administered during all treatment periods, except during the no treatment period. The P-values in the figure are from the primary analysis Figure 4 Time-course of sodium and potassium excretion in Study 2. The vertical dotted line at time 0 indicates when AZD9977 and/or eplerenone was administered. Fludrocortisone was administered from -2 to 8 h during all treatment periods, except during the no treatment period. The effects on sodium excretion were greater than the effects on potassium excretion, hence the effects noted in the primary endpoint were primarily driven by changes in sodium excretion indicated by the results in Part B of Study 1 (data not shown). In addition, the low renal clearance of AZD9977 suggest that dose adjustment is unlikely to be required in patients with renal impairment.
Study 2 utilized fludrocortisone to investigate the pharmacodynamic effects of AZD9977 on urinary electrolytes. As AZD9977 was not expected to have more than minimal effect on urinary electrolyte excretion the pharmacological effect was anticipated to attenuate the electrolyte effects of eplerenone when the two drugs were coadministered. Doses approximately twice as high as the approved eplerenone dose and the projected clinical dose of AZD9977 were used to ensure distinct effects of both eplerenone and AZD9977 on urinary sodium and potassium excretion. The clinical study design was a development of previously reported studies of MRAs [18, 30, 33] primarily by using a cross-over design to gain statistical power, the addition of a no treatment period characterizing the urinary electrolyte excretion in the untreated setting, and the coadministration of a modulator with an MRA. The design improvements would also have allowed demonstration of pharmacological activity also if AZD9977 would have lacked effect on urinary electrolyte excretion, as in preclinical studies.
Unexpectedly, AZD9977 exhibited similar electrolyte excretion as eplerenone in Study 2, and when coadministered with eplerenone, the effects of AZD9977 and eplerenone were additive. The study thus failed to prove AZD9977 lacks electrolyte effects also in man. The study also did not conclusively prove target engagement, but AZD9977 did clearly exhibit a pharmacology consistent with interaction with MR at the projected therapeutic exposure.
To better understand the clinical results preclinical experiments were performed studying the effects of AZD9977 and eplerenone on fludrocortisone vs. aldosterone stimulated MR, as the two main differences between Study 2 and the preceding preclinical experiments were the species studied and the MR agonist used. In subsequent studies in rats, AZD9977 reversed fludrocortisone induced sodium retention significantly, but had limited effect on aldosterone induced sodium retention, while eplerenone significantly antagonized sodium retention induced by both aldosterone and fludrocortisone [34] .
The data indicate that fludrocortisone based pharmacodynamic clinical studies may be appropriate for traditional MRAs as previously argued [18] , but future clinical studies assessing MR modulators in healthy volunteers could possibly benefit from using endogenous or exogenous aldosterone instead of fludrocortisone to activate MR. While the translation of fludrocortisone studies in healthy volunteers to potassium retention in patients is reasonably well established for MR antagonists [18] , the same translation for MR modulators may not be as straightforward.
A recent study by Preston et al. [35] succeeded to demonstrate a 3.5-fold higher Na + /K + -ratio over 24 h in subjects on a low salt diet and receiving a single 400 mg dose of eplerenone vs. placebo. The design used represents an alternative way of assessing electrolyte effects of MR modulators in the future without the need for an exogenous agonist, essentially using endogenous aldosterone rather than exogenous fludrocortisone to activate MR [35] . Study 1 explored high doses of AZD9977, but was not prospectively designed to assess urinary electrolytes, lacked a positive control and did not utilize a low salt diet. The results could therefore not be used to assess conclusively whether AZD9977 has differentiated effects on urinary electrolytes compared to MRAs, but the data suggest a limited effect, if any ( Figure 5 ). While the results in Study 2 were unexpected, the combined clinical data presented here and preclinical data presented elsewhere do not exclude the possibility that Figure 5 Urinary electrolyte excretion in Study 1. The amount of sodium (left) and potassium (right) excreted from 2 to 8 h post dosing (same time interval as the primary endpoint in Study 2) is presented for all studied subjects. Formal statistical analysis was not performed due to the study design with sequential rather than parallel cohorts and the low patient numbers Initial development of MR modulator AZD9977 AZD9977 may be superior to classical MRAs with regards to potassium retention. The data presented do, however, offer novel insights into the complexity of MR pharmacology and the refined approaches needed to study MR modulators in the clinical setting. MR modulators may not only represent promising new therapeutic opportunities to attenuate CKD progression and decrease cardiovascular morbidity and mortality, but also valuable tools to increase our understanding of MR biology. Future clinical studies building on the knowledge gained in Study 2 and the subsequent preclinical experiments will be performed to conclusively assess if AZD9977 has any benefit over currently available MRAs, not only in preclinical models, but also in patients.
